Summit Therapeutics Ownership
| SMMT Stock | USD 19.00 0.58 3.15% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 708 M | Current Value 727 M | Avarage Shares Outstanding 159.1 M | Quarterly Volatility 241.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Summit |
Summit Stock Ownership Analysis
About 84.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.23. Summit Therapeutics PLC had not issued any dividends in recent years. The entity had 1:1 split on the 21st of September 2020. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Summit Therapeutics PLC contact Robert Duggan at 650 460 8308 or learn more at https://www.summittxinc.com.Besides selling stocks to institutional investors, Summit Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Summit Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Summit Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Summit Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Summit Therapeutics Insider Trades History
About 84.0% of Summit Therapeutics PLC are currently held by insiders. Unlike Summit Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Summit Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Summit Therapeutics' insider trades
Summit Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Summit Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Summit Therapeutics PLC backward and forwards among themselves. Summit Therapeutics' institutional investor refers to the entity that pools money to purchase Summit Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Trust Advisors L.p. | 2024-06-30 | 788.1 K | Pictet Asset Manangement Sa | 2024-06-30 | 708.6 K | Td Asset Management Inc | 2024-09-30 | 694.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 674.2 K | Citadel Advisors Llc | 2024-09-30 | 650.8 K | Goldman Sachs Group Inc | 2024-06-30 | 453.9 K | Balyasny Asset Management Llc | 2024-09-30 | 431.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 402.2 K | Barclays Plc | 2024-06-30 | 387.3 K | Baker Bros Advisors Lp | 2024-09-30 | 24.4 M | Vanguard Group Inc | 2024-09-30 | 10.9 M |
Summit Therapeutics PLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Summit Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Summit Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Summit Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Summit Therapeutics Outstanding Bonds
Summit Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Summit Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Summit bonds can be classified according to their maturity, which is the date when Summit Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Summit Therapeutics Corporate Filings
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 26th of September 2024 Other Reports | ViewVerify | |
ASR | 19th of September 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.